Test Price
2,800 AED✅ Home Collection Available
COL1A1 Gene Osteogenesis Imperfecta Genetic Test in UAE | AED 2,800 | NGS Sequencing
Executive Summary & Core Metrics
Our COL1A1 Genetic Test provides definitive molecular diagnosis for Osteogenesis Imperfecta through whole-gene Next Generation Sequencing. Clinical supervision is provided by DHA-licensed Consultant Medical Geneticist Lina Osama Zaki Quteineh (DHA ID: 9294403). Insurance verification is available directly via WhatsApp at +971 54 548 8731. All procedures comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, and Federal Decree-Law No. 4 of 2016 on Medical Liability for patient consent and clinical safety.
The test achieves a diagnostic sensitivity exceeding 99.9% across all coding exons, splice sites, and deep intronic regions of the COL1A1 gene. Turnaround time is 3–4 weeks from sample receipt. VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection is available daily from 8 AM to 11 PM for standard peripheral blood specimen retrieval.
Test Overview & Methodology
This test analyzes the entire COL1A1 gene using Next Generation Sequencing (Illumina NovaSeq platform) to identify pathogenic and likely pathogenic variants associated with Osteogenesis Imperfecta. Bioinformatic interpretation follows ACMG/AMP classification guidelines and includes all coding regions, exon-intron boundaries, and known deep intronic mutations.
| Feature | Our COL1A1 NGS Test | Standard Single-Gene Sequencing |
|---|---|---|
| Precision | >99.9% sensitivity, all coding regions covered | ~95% sensitivity, may miss deep intronic variants |
| Method | Next Generation Sequencing (Illumina NovaSeq) with 100x coverage | Sanger sequencing, exon-by-exon |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Clinical Interpretation | In-depth bioinformatic report with ACMG classification | Basic variant report, limited classification |
Physician Insight & Safety Protocols
“COL1A1 sequencing must be interpreted within the broader clinical and radiographic context. A positive finding confirms a genetic predisposition to Osteogenesis Imperfecta, but disease severity is modulated by additional genetic modifiers, collagen cross-linking efficiency, and environmental factors. I strongly advise all patients to retain their current management plan—including bisphosphonate therapy, calcium supplementation, and physiotherapy—until a comprehensive post-test consultation has been conducted by your treating metabolic bone specialist.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠ Medication Advisory: Prescribed Therapy Continuation
Do not discontinue, pause, or alter any prescribed medications—especially bisphosphonates, vitamin D, or calcium supplements—without explicit written instruction from your managing physician. Abrupt cessation of anti-resorptive therapy may increase fracture risk and compromise bone mineral density gains.
Exclusion Criteria & Emergency Red Flags
- This test is not intended for individuals currently experiencing an acute medical emergency.
- Not suitable for patients who cannot provide a peripheral blood sample via venipuncture.
- For minors under 18 years, parental or legal guardian consent is mandatory in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Red Flags: Sudden onset of bone fractures, acute chest pain, unexplained dyspnea, or rapid neurological deterioration requires immediate emergency department evaluation—do not delay care pending genetic test results.
Patient FAQ & Clinical Guidance
1. What does the COL1A1 gene NGS test detect?
This targeted NGS assay identifies inherited and de novo mutations in the COL1A1 gene that cause Osteogenesis Imperfecta. The test covers all coding exons, flanking splice sites, and clinically relevant deep intronic regions, delivering a diagnostic yield exceeding 99.9% for classical collagen type I disorders. The result informs orthopaedic management, fracture prevention planning, and family cascade screening.
2. How is the sample collected and what is the expected turnaround time?
A standard peripheral blood sample is collected via our VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection service, available daily from 8 AM to 11 PM. DHA-licensed phlebotomists perform a sterile venipuncture using chilled transport kits maintaining 2–8°C integrity. Results are delivered within 3–4 weeks from sample receipt, including a comprehensive bioinformatic report with ACMG variant classification.
3. Is the COL1A1 genetic test covered by insurance in the UAE?
Many major UAE health insurers provide coverage for molecular genetic testing of Osteogenesis Imperfecta when a clinical indication is established by a specialist. We verify your insurance eligibility directly via WhatsApp at +971 54 548 8731. Our insurance liaison team streamlines pre-authorization to reduce out-of-pocket expenses and coordinate direct billing where applicable.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE complies fully with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted in transit and at rest, and access is restricted to authorized clinical personnel only. Patient consent for genetic testing is obtained in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring informed decision-making prior to sample collection.
Clinical & Logistical Metadata
| Test Name | COL1A1 Gene Osteogenesis Imperfecta Genetic Test (NGS) |
| Price (AED) | AED 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (2–5 mL collected in EDTA tube) |
| Methodology Used | Next Generation Sequencing (Illumina NovaSeq 6000, 100x coverage, paired-end 150 bp) |
| ICD-10-CM Code | Q78.0, Z14.8, Z31.5 |
| LOINC Code | 69548-6 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians